The BioPharm Brief: IL-23 Pathway Expansion Signals Next Wave of Immunology Lifecycle Development

Welcome to The BioPharm Brief, your daily snapshot of the developments shaping biopharmaceutical research, regulatory progress, and clinical innovation. Today’s update focuses on a regulatory milestone that could further expand treatment options for patients living with psoriatic arthritis.
In the United States, FDA has accepted for review a supplemental biologics license application for tildrakizumab from Sun Pharmaceutical Industries, seeking approval to treat adults with active psoriatic arthritis. Tildrakizumab, marketed as Ilumya, is a monoclonal antibody that selectively targets the interleukin-23 pathway, a key inflammatory driver in several immune-mediated diseases. The therapy is already approved in the US for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.